Inhaled Interferon Beta Increased Likelihood Of Recovery Among Hospitalized COVID-19 Patients, Preliminary Findings Show

Financial Times: Immunosuppressant drug shows promise for Covid-19 patients
“An initial trial showing that an immunosuppressant drug can significantly increase the likelihood of recovery among patients hospitalized by Covid-19 sent the share price of biotech company Synairgen soaring on Monday. In a study involving 101 patients from nine U.K. hospitals, those who were given interferon beta — which is commonly used to treat multiple sclerosis and thyroid dysfunction — were more than twice as likely to recover and were 79 percent less likely to develop a more severe version of the disease. Their breathlessness was also ‘markedly reduced,’ the company said…” (Gross/Mancini, 7/20).

Additional coverage of the study is available from BBC, CBC, New York Times, and UPI.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.